Pioneering pharmaceutical innovative therapies for the treatment of androgenetic alopecia start phase 3 clinical trials in China

On November 24, 2021, Kintor Pharma announced that its potential "first-in-class" new drug Furitan (KX-826) for the treatment of male androgenetic alopecia (AGA) Phase 3 clinical trials The trial application has been approved by the National Medical Products Administration (NMPA) of China

This randomized, double-blind, multi-center, placebo-controlled phase 3 trial plan enrolled 416 subjects, and the trial time was 24 weeks.

Freetann is an androgen receptor antagonist specially designed for topical application in the treatment of androgenic alopecia.

On September 8 this year, Kaifeng Pharmaceutical announced that the Phase 2 clinical trial of Freitan for the treatment of male androgenetic alopecia patients has reached the primary endpoint, showing that the drug has good efficacy and safety, and confirmed the Phase 3 Dosage for clinical trials

The upcoming Phase 3 clinical trials are planned to be carried out in more than 20 hospitals in China.

Reference materials:

[1] Kintor Pharma Receives IND Clearance by NMPA for KX-826's Pivotal Study to Treat Male Alopecia Patients.

[2] The registered phase III clinical trial of Furitan in the treatment of male androgenetic alopecia was approved by NMPA.